|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
16 October 2023 |
|
Main ID: |
ChiCTR2200057381 |
|
Date of registration:
|
2022-03-10 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy
|
|
Scientific title:
|
Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy |
|
Date of first enrolment:
|
2022-03-01 |
|
Target sample size:
|
rituximab group:68;control:135; |
|
Recruitment status: |
Pending |
|
URL:
|
https://www.chictr.org.cn/showproj.html?proj=153418 |
|
Study type:
|
Observational study |
|
Study design:
|
Cohort study
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Danxia Zheng
|
|
Address:
|
49 Huayuan North Road, Haidian District, Beijing
100191
|
|
Telephone:
|
+86 13522758603 |
|
Email:
|
dxheng@sina.com |
|
Affiliation:
|
Peking University Third Hospital |
|
|
Name:
|
Danxia Zheng
|
|
Address:
|
49 Huayuan North Road, Haidian District, Beijing
100191
|
|
Telephone:
|
+86 13522758603 |
|
Email:
|
dxheng@sina.com |
|
Affiliation:
|
Peking University Third Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Clinical diagnosis of nephrotic syndrome;
2. Renal biopsy for diagnosis of IMN;
3. Blood PLA2R antibody>20IU/ml;
4. Age: 18-80 (inclusive), regardless of gender;
5.eGFR>30 ml/min.
Exclusion criteria: 1. Renal pathology indicates that in addition to IMN, there are also other kidney diseases, such as diabetes nephropathy;
2. Secondary IMN, such as systemic lupus erythematosus, chronic hepatitis B, tuberculosis, tumor, etc.
Age minimum:
18
Age maximum:
80
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
membranous nephropathy
|
|
Intervention(s)
|
|
rituximab group:rituximab;control:hormone combined with cyclophosphamide;
|
|
Primary Outcome(s)
|
|
nephrotic syndrome outcome;renal function;
|
|
Secondary Outcome(s)
|
|
complications;
|
|
Source(s) of Monetary Support
|
|
Peking University third Hostipal
|
|
Ethics review
|
Status: Approved
Approval date: 03/03/2022
Contact:
Liang Lijun
+86 10 82265883
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|